Todd McCarty
Infectious Disease · Birmingham, ALNPI 1790002046
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $19,776 of the $19,776 with a category attached, or 100.0%. 5 manufacturers reported payments, led by Pfizer at 51.9% of the total. 2025 is the largest year on record at $7,108, 7.1 times the $1,000 reported in 2020.
Across 32 payments — averaging $618.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$10K
- GSK$6K
- Genmark Diagnostics, Inc.$2K
- T2 Biosystems, Inc.$2K
- ZOLL Medical Corporation$407
Across 11 payments — averaging $29,347 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Scynexis, Inc.$138K
- T2 Biosystems, Inc.$99K
- Cidara Therapeutics, Inc.$73K
- Pfizer$12K
What the payments were for
- Consulting fees$19,776100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 27 | $10,270 |
| GSK | 1 | $5,525 |
| Genmark Diagnostics, Inc. | 2 | $2,000 |
| T2 Biosystems, Inc. | 1 | $1,575 |
| ZOLL Medical Corporation | 1 | $407 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ePlex$2,000
- T2Dx Instrument$1,575
- LITFULO$525
How this compares
$19,776 in reported general payments places this provider in the 85th percentile of 104 infectious disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 24 | $3,177 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Birmingham
- John BaddleyBirmingham$113K
- Christina MuznyBirmingham$111K
- Sonya HeathBirmingham$80K
- William GeislerBirmingham$63K
- Edward HookBirmingham$61K
- Edgar OvertonBirmingham$46K
- Jane SchwebkeBirmingham$42K
- Peter PappasBirmingham$25K
- Jeanne MarrazzoBirmingham$23K
- Anurag GandhiBirmingham$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.